Decoupling Immunotherapy Toxicity and Cancer Response

Recruiting now

Conditions studied: Tumor, Cardiovascular

In brief

This study is a novel evaluation of cardiotoxicity after ICI therapy based on traditional CV risk factors with the addition of metabolomic profiles, epigenetic aging, and CHIP. It is not an extension of previous work in ICI therapy.

Key facts

Study ID

NCT07382752

Run by

M.D. Anderson Cancer Center

People needed

1200

Starts

2026-01-09

Expected to finish

2030-06-30

Last updated by the study team

2026-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years
• Plan to start immune checkpoint inhibitor for cancer therapy

You may not qualify if…

• No baseline blood collection prior to initiation
• At time of evaluation not determined to be a good candidate for evaluation of outcome events by the principal investigator

Where it is running

• The University of Texas M. D. Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.